Peter earned his Ph.D in molecular biology (John Innes Centre, Norwich) after which he went on to hold an academic “post-doc” position in Cambridge University.
Peter was co-founder of IONTAS and Group Leader in 2012. As a Group Leader, Peter designed and executed discovery/engineering strategies to deliver pre-clinical lead antibodies (and other protein therapeutics) for a wide variety of indications, including oncology, autoimmune diseases, analgesia, and blood disorders.
In 2020, Peter became CTO of IONTAS, providing strategic vision for technology platforms, including development, implementation and integration of biologics discovery and engineering capabilities.
Peter is responsible for delivery of the antibody discovery & protein engineering portfolio and has led numerous successful biotherapeutic drug discovery campaigns, with several of the resultant molecules now entering the clinic.